Surveillance of hepatocellular carcinoma (HCC) patients using Protein Induced by Vitamin K (PIVKA-II): A cost-utility analysis for Hong Kong
PLOS One · 17.07.2026 · 21 (7) · e0353882
DOI: 10.1371/journal.pone.0353882 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, online erschienen am 17.07.2026. Verfasst von Man-Fung Yuen und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, School of Clinical Medicine & State Key Laboratory of Liver Research, The University of Hong Kong and Queen Mary Hospital, Ho…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Protein Precursors, Biomarkers. Die Arbeit nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Roche Diagnostics.
Abstract (Originalsprache)
Background & Aims Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death in Hong Kong. Common risk factors include chronic hepatitis B (CHB) infection and/ or liver cirrhosis (LC). Routine HCC surveillance using ultrasound plus alpha-fetoprotein (AFP) for patients with these conditions is recommended, but many patients still face limited access to ultrasound. For these, biomarker-based surveillance using a combination of protein induced by vitamin K absence or antagonist-II (PIVKA-II) plus AFP could provide a valuable alternative.
Methods
This study compared the cost-utility of routine HCC surveillance using ‘PIVKA-II + AFP’ to the recommended standard-of-care in Hong Kong: surveillance using ‘US + AFP’. A health economic model using a Markov-microsimulation framework was adapted using published local data and settings. The model was used to compare diagnostic outcomes, overall costs, quality-adjusted life years (QALYs), and cost-utility of the alternative HCC surveillance methods.
Results
Compared to the current recommended standard-of-care, the results suggested that HCC surveillance using ‘PIVKA-II + AFP’ could improve detection of HCC during early-stage disease by 4.6 percentage points, thus enabling access to more effective treatment options for some patients. It could also reduce false positive diagnoses by 7.2%, which could alleviate the need for costly confirmatory testing. Overall, PIVKA-II + AFP’ was associated with a gain of 0.019 QALYs and cost savings of HK $ 4,144 per individual. The results were particularly favorable for non-cirrhotic CHB patients.
Conclusions
HCC surveillance using ‘PIVKA-II + AFP’ could be a feasible option for patients with CHB and/ or LC who face limited access to ultrasound-based surveillance. The combination has the potential to improve early-stage HCC detection, facilitating timely intervention and improving both survival outcomes and patient quality of life.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medicine, School of Clinical Medicine & State Key Laboratory of Liver Research, The University of Hong Kong and Queen Mary Hospital, Hong Kong, China.
- Vista Health Private Limited, Singapore, Singapore.
- Roche Diagnostics (Asia Pacific) Limited, Singapore, Singapore.
- Roche Hong Kong Limited, Hong Kong SAR, China.
ORCID-Profile: David Wastlund, Junqiao Chen
Förderung
- Roche Diagnostics
Zitieren
APA
Yuen, M. F., Wastlund, D., Lin, T. T. Y., Zheng, Q., Chen, J., & Ko, K. L. (2026). Surveillance of hepatocellular carcinoma (HCC) patients using Protein Induced by Vitamin K (PIVKA-II): A cost-utility analysis for Hong Kong. PLOS One, 21(7), e0353882. https://doi.org/10.1371/journal.pone.0353882
Vancouver
Yuen MF, Wastlund D, Lin TTY, Zheng Q, Chen J, Ko KL. Surveillance of hepatocellular carcinoma (HCC) patients using Protein Induced by Vitamin K (PIVKA-II): A cost-utility analysis for Hong Kong. PLOS One. 2026;21(7):e0353882. doi:10.1371/journal.pone.0353882
BibTeX
@article{Yuen2026,
author = {Yuen, Man-Fung and Wastlund, David and Lin, Tammie Tan Yan and Zheng, Qishi and Chen, Junqiao and Ko, Kwan-Lung},
title = {Surveillance of hepatocellular carcinoma (HCC) patients using Protein Induced by Vitamin K (PIVKA-II): A cost-utility analysis for Hong Kong},
journal = {PLOS One},
year = {2026},
volume = {21},
number = {7},
pages = {e0353882},
doi = {10.1371/journal.pone.0353882}
}
EUVIMED